EuBiologics Statistics

Total Valuation

EuBiologics has a market cap or net worth of KRW 468.79 billion. The enterprise value is 465.52 billion.

Market Cap	468.79B
Enterprise Value	465.52B

Important Dates

The last earnings date was Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

EuBiologics has 36.62 million shares outstanding.

Current Share Class	36.62M
Shares Outstanding	36.62M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	0.06%
Owned by Institutions (%)	5.12%
Float	29.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.76
PB Ratio	4.47
P/TBV Ratio	4.35
P/FCF Ratio	24.02
P/OCF Ratio	17.72
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 28.46, with an EV/FCF ratio of 23.85.

EV / Earnings	-33.54
EV / Sales	6.71
EV / EBITDA	28.46
EV / EBIT	64.78
EV / FCF	23.85

Financial Position

The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.14.

Current Ratio	1.63
Quick Ratio	0.77
Debt / Equity	0.14
Debt / EBITDA	0.88
Debt / FCF	0.76
Interest Coverage	15.78

Financial Efficiency

Return on equity (ROE) is -13.70% and return on invested capital (ROIC) is 3.78%.

Return on Equity (ROE)	-13.70%
Return on Assets (ROA)	3.07%
Return on Invested Capital (ROIC)	3.78%
Return on Capital Employed (ROCE)	6.11%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.44
Inventory Turnover	2.26

Taxes

In the past 12 months, EuBiologics has paid 745.04 million in taxes.

Income Tax	745.04M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.11% in the last 52 weeks. The beta is 1.56, so EuBiologics's price volatility has been higher than the market average.

Beta (5Y)	1.56
52-Week Price Change	-2.11%
50-Day Moving Average	12,315.40
200-Day Moving Average	12,306.05
Relative Strength Index (RSI)	45.40
Average Volume (20 Days)	215,212

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EuBiologics had revenue of KRW 69.37 billion and -13.88 billion in losses. Loss per share was -381.00.

Revenue	69.37B
Gross Profit	33.96B
Operating Income	7.70B
Pretax Income	-14.61B
Net Income	-13.88B
EBITDA	16.87B
EBIT	7.70B
Loss Per Share	-381.00

Full Income Statement

Balance Sheet

The company has 11.49 billion in cash and 14.78 billion in debt, giving a net cash position of -3.29 billion or -89.76 per share.

Cash & Cash Equivalents	11.49B
Total Debt	14.78B
Net Cash	-3.29B
Net Cash Per Share	-89.76
Equity (Book Value)	104.82B
Book Value Per Share	3,055.10
Working Capital	16.07B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 26.45 billion and capital expenditures -6.94 billion, giving a free cash flow of 19.52 billion.

Operating Cash Flow	26.45B
Capital Expenditures	-6.94B
Free Cash Flow	19.52B
FCF Per Share	532.85

Full Cash Flow Statement

Margins

Gross margin is 48.96%, with operating and profit margins of 11.10% and -20.01%.

Gross Margin	48.96%
Operating Margin	11.10%
Pretax Margin	-21.07%
Profit Margin	-20.01%
EBITDA Margin	24.32%
EBIT Margin	11.10%
FCF Margin	28.13%

Dividends & Yields

EuBiologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.13%
Shareholder Yield	n/a
Earnings Yield	-2.96%
FCF Yield	4.16%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

EuBiologics has an Altman Z-Score of 3.5 and a Piotroski F-Score of 6.

Altman Z-Score	3.5
Piotroski F-Score	6